Arcus Biosciences Current Ratio 2017-2023 | RCUS
Arcus Biosciences current ratio from 2017 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Arcus Biosciences Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-03-31 |
$1.02B |
$0.18B |
5.67 |
| 2022-12-31 |
$1.07B |
$0.19B |
5.53 |
| 2022-09-30 |
$1.10B |
$0.18B |
6.22 |
| 2022-06-30 |
$1.23B |
$0.16B |
7.48 |
| 2022-03-31 |
$1.26B |
$0.16B |
7.84 |
| 2021-12-31 |
$1.26B |
$0.17B |
7.60 |
| 2021-09-30 |
$0.55B |
$0.14B |
3.82 |
| 2021-06-30 |
$0.75B |
$0.13B |
5.72 |
| 2021-03-31 |
$0.84B |
$0.13B |
6.38 |
| 2020-12-31 |
$0.74B |
$0.12B |
6.05 |
| 2020-09-30 |
$0.80B |
$0.16B |
4.90 |
| 2020-06-30 |
$0.47B |
$0.04B |
11.78 |
| 2020-03-31 |
$0.17B |
$0.02B |
7.91 |
| 2019-12-31 |
$0.19B |
$0.02B |
8.49 |
| 2019-09-30 |
$0.20B |
$0.02B |
9.52 |
| 2019-06-30 |
$0.23B |
$0.03B |
8.59 |
| 2019-03-31 |
$0.25B |
$0.02B |
12.89 |
| 2018-12-31 |
$0.26B |
$0.02B |
15.29 |
| 2018-09-30 |
$0.27B |
$0.02B |
15.97 |
| 2018-06-30 |
$0.27B |
$0.02B |
16.33 |
| 2018-03-31 |
$0.28B |
$0.01B |
19.78 |
| 2017-12-31 |
$0.18B |
$0.01B |
13.90 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2017-06-30 |
$0.00B |
|
0.00 |
| 2017-03-31 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.611B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
